A new startup medical imaging company will use technology developed at the University of Nebraska-Lincoln.
Ground Fluor Pharmaceuticals Inc. will use the technology to
help it and other companies better manufacture imaging agents for
positron emission tomography, or PET, scans.
A PET scan is a nuclear medicine imaging technique that provides
information about the function and metabolism of the body's organs.
PET scans are used mainly to study patients with cancer, heart
disease and neurodegenerative disorders such as Parkinson's and
UNL fluorine chemist Stephen DiMagno discovered a way to improve
PET scans, which may also help expand the types of diseases that
PET scans can diagnose.
Ground Fluor Pharmaceuticals will house its research and
development facility in Lincoln. The company will also have an
office in Cambridge, Mass.